ArticleFrontiers in immunology2023
Characteristics of cardiac involvement in immune-mediated necrotizing myopathy.
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Seronegative Immune-Mediated Necrotizing Myopathy: An Overview for Optimal Clinical Management.Current rheumatology reports · 2026Review
- Immune-mediated necrotizing myopathies: clinico-serological features and treatment outcomes of a large Italian cohort of patients.Journal of neurology · 2026Article
- Cardiac involvement in immune-mediated necrotizing myopathy: a case report with insights from cardiac magnetic resonance imaging.EULAR rheumatology open · 2026Article
- Anti-signal Recognition Particle Antibody-associated Myopathy with a Dermatomyositis-like Rash Successfully Treated for Concomitant Cardiac Involvement with Intravenous Immunoglobulin Therapy.Internal medicine (Tokyo, Japan) · 2026Article
- Fatal Cardiomyopathy Secondary to Seronegative Immune-Mediated Necrotizing Myopathy: A Case Report.The American journal of case reports · 2026Article
- Novel phenotypes of immune-mediated necrotizing myopathy identified independent of myositis-specific antibody specificity that improve prognostic stratification.Frontiers in immunology · 2026Article
- A Case of Anti-SRP Immune-mediated Necrotizing Myopathy Following Suspected Coxsackie B4 Infection: Exploring a Viral Trigger Hypothesis.Journal of community hospital internal medicine perspectives · 2026Article
- Immune-Mediated Necrotizing Myopathy: A Systematic Review of Antibody-Specific Mechanisms and Treatment Outcomes.Cureus · 2025Review
- A Case of Anti-3-Hydroxy-Methylglutaryl-Coenzyme a Reductase (Anti-HMGCR) Immune-Mediated Necrotizing Myopathy.Cureus · 2025Article
- Risk factors and diagnostic biomarkers for asymptomatic immune checkpoint inhibitor-related myocarditis in patients with esophageal cancer after immunotherapy.World journal of gastroenterology · 2025Article
- Idiopathic Inflammatory Myopathies: Recent Evidence Linking Pathogenesis and Clinical Features.International journal of molecular sciences · 2025Review
- Cardiovascular events in patients with myositis: results from a French retrospective cohort.RMD open · 2025Observational
- Epidemiology of myositis.Current opinion in rheumatology · 2025Review
- Anti-HMGCR myopathy: a first case report from North Africa and literature insights.Frontiers in immunology · 2025Review
- CD163+ macrophage density in perimysial connective tissue associated with prognosis in IMNM.Annals of clinical and translational neurology · 2024Article
- Retrospective Study Shows That Serum Levels of Chemokine CXCL10 and Cytokine GDF15 Support a Diagnosis of Sporadic Inclusion Body Myositis and Immune-Mediated Necrotizing Myopathy.Brain sciences · 2023Article
- Evidence of Cardiac Involvement in a Patient With Necrotizing Autoimmune Myopathy (NAM).Cureus · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the characteristics of cardiac involvement due to Immune-mediated Necrotizing Myopathy (IMNM). Methods: Patients diagnosed with Immune-mediated Necrotizing Myopathy (IMNM) who attended the Department of Neurology and the Department of Rheumatology and Immunology at the First Medical Center of the PLA General Hospital between February 2011 and June 2022 were collected. Clinicopathological diagnosis of IMNM was performed according to the criteria established by the European Neuromuscular Center (ENMC). All patients underwent muscle biopsy and Myositis-specific antibodies (MSAs) testing. Information included age, gender, disease duration, intramuscular and extramuscular manifestations, laboratory findings (including creatine kinase, lactate dehydrogenase levels, troponin T, myoglobin and atrial natriuretic peptide), electromyography, skeletal muscle pathology and immunohistochemical staining. Results: A total of 57 patients were included in this study. Of the serological tests, 56.1% (32/57) were positive for SRP, 21.1% (12/57) were positive for HMGCR and 22.8% (13/57) were seronegative. Thirty patients (52.6%, 30/57) presented with varying degrees of cardiac involvement. We performed ECG in 23 patients and found 6 patients with arrhythmia (26.1%), 12 patients with myocardial ischemia (52.2%), and 7 patients with acute coronary syndrome (ST elevation and non-ST elevation myocardial infarction) (30.4%), and 4 patients with left axis deviation or left ventricular high voltage, suggesting left ventricular hypertrophy (17.4%). Cardiac ultrasound was performed in 14 patients and 3 showed pericardial effusion (21.4%); Decreased left ventricular ejection fraction and atrial enlargement were 2 each; 8 showed a decrease in left ventricular diastolic function (57.1%). In addition, one patient had myocardial edema. Conclusion: Cardiac involvement is not uncommon in IMNM. However, besides clearly statistically significant differences in the disease course, and in the values of troponin T and myoglobin, our data did not show any statistically significant difference in other features of cardiac involvement between patients with different subtypes of IMNM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.